Pertussis vaccination Market Size, Share, Growth, and Industry Analysis, By Type (Acellular Vaccines and Whole-cell Vaccines), By Application (12 Months Below and 12 Months After), and Regional Forecast to 2032

Last Updated: 06 January 2025

PERTUSSIS VACCINATION MARKET OVERVIEW

The global pertussis vaccination market size was USD 5.187 billion in 2023 and is projected to touch USD 7.10 billion by 2032, exhibiting a CAGR of 3.5% during the forecast period.

The respiratory disease pertussis, occasionally appertained to as whooping cough, affects the nose and throat. Although it has been present for centuries, vaccinations can help it. The whooping cough- causing Borrelia bacteria are defended from by the pertussis vaccination, which is administered intravenously. It has a poison that has been rendered inactive but is still set up in Bordetella pertussis cells. The respiratory infection pertussis, generally known as whooping cough, is brought on by the bacteria Bordetella pertussis. Multitudinous quick coughing fits accompanied by an inspiratory whoop and vomiting following coughing fits are among the symptoms.

The pertussis vaccination market is expanding due to increasing awareness of whooping cough’s severity, rising vaccination rates, and government initiatives promoting immunization. Innovations in vaccine formulations, combined with strategic partnerships among healthcare providers, are enhancing access and acceptance. The focus on public health initiatives further drives global demand for pertussis vaccines.

GLOBAL CRISES IMPACTING PERTUSSIS VACCINATION MARKETCOVID-19 IMPACT

Pertussis vaccination Industry had a positive Effect Due to ristrictions during COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The dynamics of the market were altered by the COVID- 19 epidemic. Since the focus changed from routine immunizations to COVID- 19 vaccines in recent years, there has been a minor decline in the market for conventional vaccines. A significant amount of work has gone into creating new specifics and vaccines to combat the virus. Following several weeks of disquisition, businesses have begun developing specifics and curatives to combat the virus.

LATEST TREND

"Pharmaceutical Businesses Initiatives for Expanding and Growing the Market"

Recent traits inside the pertussis vaccination industry include integration with pharmaceutical business. Due to rising public awareness of the benefits of DTP vaccines worldwide, particularly in developing countries, the market for DTP vaccines is prognosticated to expand steadily throughout the projected period. Increased efforts by pharmaceutical companies to improve vaccine R&D are projected to support the market growth for DTP vaccines. Also, cooperation among those involved in the vaccine business is pivotal in order to combine all available product development strategies and raise the liability that immunization will be made extensively available.

PERTUSSIS VACCINATION MARKET SEGMENTATION

BY TYPE

Based on Type, the global market can be categorized into Acellular Vaccines and Whole-cell Vaccines

• Acellular Vaccines: Acellular vaccines represent a further ultramodern approach to pertussis prevention. These vaccines are composed of purified factors of the Bordetella pertussis bacterium rather than the whole cell, which significantly reduces the threat of side goods. Acellular vaccines are particularly favoured in high- income countries, where safety enterprises and public perception play a pivotal part in vaccination choices. The advanced manufacturing costs associated with acellular vaccines are neutralizing by their increased acceptance and compliance, which continue to drive their market growth.
• Whole-cell Vaccines: Whole- cell vaccines have been in use for several decades and were among the first vaccines developed to combat pertussis. Despite their efficacy, these vaccines are frequently associated with advanced rates of adverse responses, which have led to a gradational decline in their operation over the times. Still, they're still current in numerous low- and middle- income countries due to their cost- effectiveness and proven efficacy in large- scale immunization programs.

BY APPLICATION

Based on application, the global market can be categorized into 12 Months Below and 12 Months After

•  12 Months Below: It is gaining elevation as substantiation suggests waning impunity from non age immunizations. Supporter boluses during non age help maintain impunity and help the resurgence of pertussis cases among teenagers, who can act as budgets for the bacterium and transmit it to vulnerable populations, including babies and the senior. School entry conditions and public health juggernauts significantly contribute to the rising uptake of pertussis supporter vaccines in this age group.
•  12 Months After: It is particularly for pregnant women, is an arising focus area in the pertussis vaccination market. Vaccinating pregnant women during the third trimester provides unresistant impunity to babe, guarding them during the first many months of life when they're most susceptible to severe pertussis. This strategy is championed by major health associations, including the WHO and the Centers for Disease Control and Prevention (CDC), and is decreasingly being espoused in public immunization guidelines. Also, supporter boluses for grown-ups, especially healthcare workers and individualities in close contact with babies, are recommended to reduce transmission pitfalls.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.  

DRIVING FACTORS

"increasing Incidence of Pertussis or Whooping Cough globally to boost the Market"

A factor in the pertussis vaccination market growth is the increasing incidence of pertussis or whooping cough globally. Pertussis is largely contagious and can be particularly severe in babies and youthful children, leading to hospitalizations and, in some cases, death. This has heightened the urgency among healthcare providers and governments to insure wide vaccination content. Public health juggernauts and educational programs emphasizing the significance of timely vaccination are gaining instigation, thereby boosting the market demand.

"Increasing Incidence of Newly Discovered and Rediscovered Infectious Diseases to Expand Market Growth"

The increasing incidences of newly discovered and rediscovered infectious diseases are another key aspect of the pertussis vaccination market. Living in more densely populated places, travelling much more constantly and over longer distances than in the history, and adding human- wildlife contact raise serious enterprises about the eventuality for new contagious conditions to spread snappily and spark afflictions over the world. Also, there's a chance that ails could spread after being purposefully introduced into an animal, human, or plant population for vicious objects. In the forthcoming times, there will continue to be an adding need for vaccines due to the adding frequency of these contagious conditions. In order to assure stronger R&D backing enterprise, a solid channel, and new vaccine openings for wide population parts and promote market growth, variables including the arrival of new conditions are necessary.

RESTRAINING FACTOR

"High Expense of Developing Vaccine"" to Potentially Impede Market Growth"

The high expense of developing vaccine poses a significant restraining factor for the growth of the Pertussis vaccination market. The process of developing vaccines requires a significant amount of capital. The cost of storing and shipping vaccinations is higher than that of any other pharmaceutical product because they need specific facilities and monitoring systems. The effectiveness and quality of vaccines can suffer from inadequate storage and delivery infrastructure. Additionally, because vaccine research has a poor success rate, businesses struggle to control operational expenses and secure initial investments. Therefore, the high cost of vaccine production and storage is limiting market expansion.

OPPORTUNITY

"The development of new and improved vaccines to Create Opportunity for the Product in the Market"

 One significant opportunity lies in the development of new and advanced vaccines. Biotechnological inventions and exploration are leading to the creation of vaccines with advanced efficacy, longer- lasting impunity, and smaller side goods. These advancements can enhance public trust and acceptance of vaccines, thereby adding vaccination rates. Also, the preface of combination vaccines, which cover against multiple conditions, offers a streamlined approach to immunization, perfecting adherence to vaccination schedules and reducing healthcare costs.

CHALLENGE

"The Vaccine Hesitancy Could Be a Potential Challenge for Consumers"

One of the primary challenges is vaccine hesitancy, driven by misinformation, artistic beliefs, and distrust in healthcare systems. Vaccine hesitancy can lead to lower vaccination rates, performing in outbreaks and undermining public health sweats. Addressing this issue requires comprehensive educational juggernauts, transparent communication from healthcare authorities, and community engagement to make trust and disband myths about vaccination. Also, logistical challenges similar as vaccine storehouse and distribution, particularly in remote and underserved areas, pose significant pitfalls to achieving high vaccination content. Ensuring robust force chain operation and structure is pivotal to prostrating these challenges and sustaining market growth.

PERTUSSIS VACCINATION MARKET REGIONAL INSIGHTS

• NORTH AMERICA 

The region dominates the pertussis vaccination market share. In North America, the market is anticipated to maintain steady growth due to high vaccination content, robust healthcare structure, and ongoing public health enterprise. The United States and Canada have well- established immunization programs and high public mindfulness about the significance of vaccination. The North American market is projected to grow at a CAGR during the cast period, driven by nonstop efforts to improve vaccination rates and address vaccine- preventable conditions.

• EUROPE

In Europe, the pertussis vaccination market is characterized by high vaccination content and strong government support for immunization programs. Countries similar as the United Kingdom, Germany, and France have comprehensive vaccination schedules and programs that insure wide access to pertussis vaccines. The European market is anticipated to grow at a moderate pace. Ongoing public health juggernauts and sweats to address vaccine hesitancy are crucial motorists of market growth in this region. Also, the preface of new and advanced vaccines is anticipated to further boost demand and enhance public health issues.

• ASIA

Asia Pacific represents a significant growth occasion for the pertussis vaccination market. The region's large and different population, coupled with adding healthcare investments and government enterprise, drives demand for vaccines. Countries similar as China, India, and Japan are fastening on expanding their immunization programs and perfecting healthcare access, particularly in pastoral and underserved areas. The Asia Pacific market is projected to grow at a CAGR of around 6.8, the loftiest among all regions. Transnational support and backing from associations similar as GAVI play a pivotal part in strengthening vaccination sweats and perfecting public health structure in this region.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through Innovation and Market Expansion"

Key enterprise players are shaping the pertussis vaccination marketplace through strategic innovation and marketplace growth. These agencies are introducing superior milling strategies to beautify the fine and nutritional profile. They are also increasing their product traces to include specialized versions like organic and vertical farming, catering to various purchaser preferences. Additionally, they may be leveraging virtual systems for greater market reach and distribution performance. By making an investment in research and improvement, improving delivery chain managements, and exploring new regional markets, those players are riding a boom and setting traits within the pertussis vaccination enterprise.

LIST OF TOP PERTUSSIS VACCINATION COMPANIES

• Sanofi Pasteur (France)
• GSK (U.K.)
• Mitsubishi Tanabe Pharma (Japan)
• KM Biologics (Japan)
• Wuhan Institute of Biological Products(China)
• Walvax Biotechnology (China)
• Chengdu Institute of Biological Products (China)
• Minhai Biotechnology (China)

KEY INDUSTRIAL DEVELOPMENT

May 2024: Mitsubishi Tanabe Pharma Corporation (MTPC), part of the Mitsubishi Chemical Group, has launched CANAGLU® OD Tablets 100 mg (Canagliflozin Hydrate) to enhance diabetes management. This SGLT2 inhibitor offers a novel approach to glycemic control, helping patients achieve better blood sugar levels. The introduction of CANAGLU® supports MTPC's commitment to advancing healthcare solutions in the diabetes market.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.